Abstract
Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.
| Original language | English |
|---|---|
| Pages (from-to) | 2390-2396 |
| Number of pages | 7 |
| Journal | Nippon rinsho. Japanese journal of clinical medicine |
| Volume | 60 |
| Issue number | 12 |
| Publication status | Published - 2002 |
| Externally published | Yes |
Fingerprint
Cite this
Etanercept. / Takeuchi, Tsutomu; Amano, Koichi.
In: Nippon rinsho. Japanese journal of clinical medicine, Vol. 60, No. 12, 2002, p. 2390-2396.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Etanercept
AU - Takeuchi, Tsutomu
AU - Amano, Koichi
PY - 2002
Y1 - 2002
N2 - Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.
AB - Etanercept is a protein comprised of the extracellular domains of two TNF receptors attached to a Fc portion of an IgG. Etanercept was approved for not only reducing signs and symptoms but inhibiting of structural damage in patients with active RA who had an inadequate response to one or more DMARDs. Moreover, combination therapy with methotrexate will be attractive for severely active patients. The proportion of patients who have discontinued therapy due to adverse events is approximately 4%. Etanercept has not raised the risk for serious infections(0.04/patient-year) as well as malignancies. There are sporadic case reports of aplastic anemia, demyelination, lupus-like conditions, which are not significant so far. Etanercept may contribute rheumatologists to manage patients with RA.
UR - http://www.scopus.com/inward/record.url?scp=0036985695&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036985695&partnerID=8YFLogxK
M3 - Article
C2 - 12510367
AN - SCOPUS:0036985695
VL - 60
SP - 2390
EP - 2396
JO - Nihon rinsho. Japanese journal of clinical medicine
JF - Nihon rinsho. Japanese journal of clinical medicine
SN - 0047-1852
IS - 12
ER -